RU2630583C2 - Аналоги цистамина, применяемые для лечения болезни паркинсона - Google Patents

Аналоги цистамина, применяемые для лечения болезни паркинсона Download PDF

Info

Publication number
RU2630583C2
RU2630583C2 RU2013137645A RU2013137645A RU2630583C2 RU 2630583 C2 RU2630583 C2 RU 2630583C2 RU 2013137645 A RU2013137645 A RU 2013137645A RU 2013137645 A RU2013137645 A RU 2013137645A RU 2630583 C2 RU2630583 C2 RU 2630583C2
Authority
RU
Russia
Prior art keywords
cystamine
disease
parkinson
pharmaceutically acceptable
patient
Prior art date
Application number
RU2013137645A
Other languages
English (en)
Russian (ru)
Other versions
RU2013137645A (ru
Inventor
Франческа СИЧЕТТИ
Клауди РУИЛЛАРД
Фредерик КАЛОН
Original Assignee
Университет Лаваль
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Университет Лаваль filed Critical Университет Лаваль
Publication of RU2013137645A publication Critical patent/RU2013137645A/ru
Application granted granted Critical
Publication of RU2630583C2 publication Critical patent/RU2630583C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
RU2013137645A 2011-02-23 2012-02-23 Аналоги цистамина, применяемые для лечения болезни паркинсона RU2630583C2 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161445577P 2011-02-23 2011-02-23
CA2732440A CA2732440C (en) 2011-02-23 2011-02-23 Cystamine analogues for the treatment of parkinson`s disease
US61/445,577 2011-02-23
CA2,732,440 2011-02-23
PCT/CA2012/050106 WO2012113079A1 (en) 2011-02-23 2012-02-23 Cystamine analogues for the treatment of parkinson's disease

Publications (2)

Publication Number Publication Date
RU2013137645A RU2013137645A (ru) 2015-02-20
RU2630583C2 true RU2630583C2 (ru) 2017-09-11

Family

ID=46717621

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2013137645A RU2630583C2 (ru) 2011-02-23 2012-02-23 Аналоги цистамина, применяемые для лечения болезни паркинсона

Country Status (11)

Country Link
US (1) US20140073694A1 (enExample)
EP (1) EP2678009B1 (enExample)
JP (1) JP6000985B2 (enExample)
KR (1) KR20140115239A (enExample)
CN (1) CN103442704A (enExample)
AU (1) AU2012220314B2 (enExample)
BR (1) BR112013021616A2 (enExample)
CA (1) CA2732440C (enExample)
MX (1) MX350195B (enExample)
RU (1) RU2630583C2 (enExample)
WO (1) WO2012113079A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI659209B (zh) * 2013-06-17 2019-05-11 地平線罕見醫學製藥有限責任公司 分析半胱胺組合物的方法
TW201618760A (zh) * 2014-11-05 2016-06-01 雷普特製藥有限公司 使用半胱胺組合物治療亨廷頓氏病之方法
CN113197851A (zh) 2015-05-06 2021-08-03 辛纳吉勒公司 包含药物粒子的药用悬浮液、用于其配给的装置、以及其使用方法
RU2766579C2 (ru) 2015-07-02 2022-03-15 ХОРАЙЗОН ОРФАН ЭлЭлСи Цистеаминдиоксигеназа-резистентные аналоги цистеамина и их применение
WO2017166139A1 (zh) 2016-03-30 2017-10-05 广东欧珀移动通信有限公司 中继传输的方法和装置
WO2020198529A1 (en) * 2019-03-26 2020-10-01 The Regents Of The University Ofcalifornia Substituted amino-thiol and amino-disulfide compounds, and uses thereof
WO2021022012A1 (en) * 2019-07-30 2021-02-04 The Regents Of The University Of California Methods and composition for treating respiratory obstructive diseases
CN119909064B (zh) * 2025-04-07 2025-08-15 北京大学深圳研究生院 胱胺衍生物或其盐以及其在制备具有抗氧化功效的药物中的应用
CN120437102B (zh) * 2025-07-09 2025-09-16 中南大学湘雅医院 胱胺在制备治疗脓毒症脑病药物中的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004069175A2 (en) * 2003-02-02 2004-08-19 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services METHODS AND COMPOSITIONS FOR THE TREATMENT OF PARKINSON’S DISEASE AND OTHER α-SYNUCLEINOPATHIES
RU2255775C1 (ru) * 2003-12-25 2005-07-10 Государственное учреждение научно-исследовательский институт неврологии Российской академии медицинских наук Способ лечения болезни паркинсона
WO2008143876A2 (en) * 2007-05-14 2008-11-27 The Trustees Of Columia University In The City Of New York Agents and assays for modulating neurodegeneration

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007089670A2 (en) * 2006-01-27 2007-08-09 The Regents Of The University Of California Enterically coated cysteamine, cystamine and derivatives thereof
EP2296462A4 (en) * 2008-06-13 2011-06-15 Teva Pharma RASAGILINE FOR INFLUENCING MORBUS PARKINSON

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004069175A2 (en) * 2003-02-02 2004-08-19 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services METHODS AND COMPOSITIONS FOR THE TREATMENT OF PARKINSON’S DISEASE AND OTHER α-SYNUCLEINOPATHIES
RU2255775C1 (ru) * 2003-12-25 2005-07-10 Государственное учреждение научно-исследовательский институт неврологии Российской академии медицинских наук Способ лечения болезни паркинсона
WO2008143876A2 (en) * 2007-05-14 2008-11-27 The Trustees Of Columia University In The City Of New York Agents and assays for modulating neurodegeneration

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BOUSQUET M et al. Cystamine metabolism and brain transport properties: clinical implications for neurodegenerative diseases. J.Neurochem. 2010 Sep;1146):1651-8 Реферат [он-лайн] [найдено 09.04.2015] (Найдено из Интернет: www.ncbi.nlm.nih.gov/pubmed/20569301). GIBRAT C et al. Cystamine prevents MPTP-induced toxicity in young adult mice via the up-regulation of the brain-derived neurotrophic factor. Prog.Neuropsychopharmacol.Biol.Psychiatry 2010 Feb 1; 34(1):193-203 Реферат [он-лайн] [найдено 09.04.2015] (Найдено из Интернет: www.ncbi.nlm.nih.gov/pubmed/19913065). STACK EC et al. Therapeutic attenuation of mitochondrial dysfunction and oxidative stress in neurotoxin models of Parkinson's disease. Biochim. Biophys. Acta 2008 Mar; 1782(3): 151-62 [он-лайн] [найдено 09.04.2015] (Найдено из Интернет: www.ncbi.nlm.nih.gov/pubmed/18206128) , c.159 2-я колонка 2-й абзац - с.160. *
BOUSQUET M et al. Cystamine metabolism and brain transport properties: clinical implications for neurodegenerative diseases. J.Neurochem. 2010 Sep;1146):1651-8 Реферат [он-лайн] [найдено 09.04.2015] (Найдено из Интернет: www.ncbi.nlm.nih.gov/pubmed/20569301). GIBRAT C et al. Cystamine prevents MPTP-induced toxicity in young adult mice via the up-regulation of the brain-derived neurotrophic factor. Prog.Neuropsychopharmacol.Biol.Psychiatry 2010 Feb 1; 34(1):193-203 Реферат [он-лайн] [найдено 09.04.2015] (Найдено из Интернет: www.ncbi.nlm.nih.gov/pubmed/19913065). STACK EC et al. Therapeutic attenuation of mitochondrial dysfunction and oxidative stress in neurotoxin models of Parkinson's disease. Biochim. Biophys. Acta 2008 Mar; 1782(3): 151-62 [он-лайн] [найдено 09.04.2015] (Найдено из Интернет: www.ncbi.nlm.nih.gov/pubmed/18206128) реферат, c.159 2-я колонка 2-й абзац - с.160. *
РУКОВОДСТВО ПО МЕДИЦИНЕ THE MERCK MANUAL Гл. ред. Р.Беркоу М., Мир 1997 т.1 с.1021 глава Болезнь Паркинсона 1-й абзац. *

Also Published As

Publication number Publication date
BR112013021616A2 (pt) 2020-09-29
US20140073694A1 (en) 2014-03-13
MX350195B (es) 2017-08-30
AU2012220314A1 (en) 2013-08-22
EP2678009A1 (en) 2014-01-01
JP2014508758A (ja) 2014-04-10
RU2013137645A (ru) 2015-02-20
KR20140115239A (ko) 2014-09-30
MX2013009608A (es) 2013-09-16
WO2012113079A1 (en) 2012-08-30
EP2678009A4 (en) 2014-08-06
AU2012220314B2 (en) 2017-04-06
CN103442704A (zh) 2013-12-11
CA2732440A1 (en) 2012-08-23
EP2678009B1 (en) 2017-11-01
CA2732440C (en) 2017-10-31
JP6000985B2 (ja) 2016-10-05

Similar Documents

Publication Publication Date Title
AU2012220314B2 (en) Cystamine analogues for the treatment of Parkinson&#39;s disease
Salamon et al. Neuroprotection in Parkinson’s disease: facts and hopes: A. Salamon et al.
Ramírez-Guerrero et al. Taurine and astrocytes: a homeostatic and neuroprotective relationship
Rausch et al. From the tyrosine hydroxylase hypothesis of Parkinson’s disease to modern strategies: a short historical overview
Wei et al. Isoflurane and sevoflurane affect cell survival and BCL-2/BAX ratio differently
Onaolapo et al. Peripheral and central glutamate dyshomeostasis in neurodegenerative disorders
Miyazaki et al. Neuroprotective effects of levetiracetam target xCT in astrocytes in parkinsonian mice
Ramli et al. A mechanistic review on toxicity effects of methamphetamine
Mahan Neuroprotective, neurotherapeutic, and neurometabolic effects of carbon monoxide
Amin et al. Optimized integration of fluoxetine and 7, 8-dihydroxyflavone as an efficient therapy for reversing depressive-like behavior in mice during the perimenopausal period
Althobaiti et al. Effects of ceftriaxone on glial glutamate transporters in Wistar rats administered sequential ethanol and methamphetamine
Esposito et al. Death in the substantia nigra: a motor tragedy
Li et al. Exosomes derived from DPA-treated UCMSCs attenuated depression-like behaviors and neuroinflammation in a model of depression induced by chronic stress
Li et al. Brain-targeted ursolic acid nanoparticles for anti-ferroptosis therapy in subarachnoid hemorrhage
Wang et al. Phytic acid attenuates upregulation of GSK-3β and disturbance of synaptic vesicle recycling in MPTP-induced Parkinson's disease models
JP5901770B2 (ja) Ｃｙｐ４ａ阻害剤を有効成分として含有する糖尿病又は脂肪肝の予防又は治療用薬学的組成物。
Wang et al. Role of glycolysis-mediated histone lactylation in microglial activation and progression of neurodegenerative diseases
Ching et al. A novel treatment strategy for glioblastoma multiforme and glioma associated seizures: increasing glutamate uptake with PPARγ agonists
Lavrova et al. Role of oxidative stress in the etiology of Parkinson’s disease: Advanced therapeutic products
Sabry et al. Harnessing melatonergic agonists and antagonists: a dual approach to alleviating depression and depression-associated insomnia
Wu et al. Bufotenidine attenuates astrocyte ferroptosis in depressive-like behaviors through targeting GluA1 to reduce neuronal lipid synthesis
Bekker An investigation of the neuroprotective properties of curcumin by monitoring autophagy and apoptosis
Henchcliffe et al. Potential therapies for mitochondrial dysfunction
CA3252573A1 (en) USE OF GLYCINE TRANSPORTER-1 ANTAGONISTS AS PROPHYLACTIC/THERAPEUTIC AGENTS FOR VASCULAR DEMENTIA AND/OR STROKE
Maple Maple syrup urine disease

Legal Events

Date Code Title Description
HE9A Changing address for correspondence with an applicant
MM4A The patent is invalid due to non-payment of fees

Effective date: 20190224